Advertisement
Icon WebMD Expert Blogs

WebMD's editorial staff on the latest news from the world of health.

Important:

The opinions expressed in WebMD User-generated content areas like communities, review, ratings, or blogs are solely those of the User, who may or may not have... Expand

The opinions expressed in WebMD User-generated content areas like communities, reviews, ratings, or blogs are solely those of the User, who may or may not have medical or scientific training. These opinions do not represent the opinions of WebMD. User-generated content areas are not reviewed by a WebMD physician or any member of the WebMD editorial staff for accuracy, balance, objectivity, or any other reason except for compliance with our Terms and Conditions. Some of these opinions may contain information about treatments or uses of drug products that have not been approved by the U.S. Food and Drug Administration. WebMD does not endorse any specific product, service or treatment.

Do not consider WebMD User-generated content as medical advice. Never delay or disregard seeking professional medical advice from your doctor or other qualified healthcare provider because of something you have read on WebMD. You should always speak with your doctor before you start, stop, or change any prescribed part of your care plan or treatment. WebMD understands that reading individual, real-life experiences can be a helpful resource, but it is never a substitute for professional medical advice, diagnosis, or treatment from a qualified health care provider. If you think you may have a medical emergency, call your doctor or dial 911 immediately.

Hide

Wednesday, February 22, 2012

Cancer Drug Shortage Over Soon, FDA Says

by Daniel J. DeNoon

Critical shortages of two important cancer drugs may soon be over, the FDA says.

Doxil, known generically as doxorubicin, is a treatment for Kaposi’s sarcoma, multiple myeloma, and treatment-resistant ovarian cancer. It’s been in critically short supply. Now new supplies are pouring in thanks to FDA approval of a Doxil alternative, Lipodox, from a company in the United Arab Emirates.

Methotrexate, hugely important in the treatment of childhood leukemia, has also been in short supply.  A new statement from the FDA suggests that the shortage already may be over.  One supplier has come through with enough methotrexate to supply the U.S. for a full month.

Fresh supplies soon will be coming in from a newly licensed Illinois plant owned by a German health group. The company should begin supplying the drug in March and will continue indefinitely.

FDA actions spurring companies to make earlier reports of possible shortages seems to be getting results. Voluntary shortage notifications have shot up sixfold.

The FDA still maintains a long list of drug shortages, including shortages of some generic ADHD drugs. Shortages of different types of drugs result from different sets of problems. The recent enlargement of the FDA’s drug-shortage office is a hopeful sign.

 

Posted by: Daniel DeNoon at 3:36 pm

Comments

Leave a comment

Subscribe & Stay Informed

WebMD Daily

Get your daily dose of healthy living, diet, exercise and health news from WebMD!

Archives

WebMD Health News